MTOR and renal cell carcinoma: Over the last 20 years, the prognosis for patients with metastatic RCC has improved thanks to the results of clinical trials with mTOR inhibitors (mTORIs), tyrosine kinase inhibitors (TKIs) or immune checkpoint inhibitors (ICIs).